Women scientists are more likely to develop treatments for women, but many of their ideas never become inventions, research by Rembrand Koning says. What would it take to make innovation more equitable?
Women are more likely to invent medical treatments for endometriosis, cervical cancer, and other female conditions, but the dearth of women scientists limits the potential for such life-saving innovations.
Female research teams are 35 percent more likely than male teams to develop medical treatments that primarily benefit women, yet an examination of biomedical patents filed over a 30-year period revealed a significant shortage of inventions targeting women’s health versus the large volume of new products for male ailments, according to a recent study by Harvard Business School professor Rembrand Koning and colleagues.
With women representing only 13 percent of patent holders in the United States, the lack of female-driven inventions may well be having a direct impact on health outcomes, Koning says. If fewer inventors are focused on, say, personalized breast cancer treatment or ovarian cancer tests, fewer lives will be saved by the resulting innovations.
“You have all these women who have great ideas, but aren't being included in the process of commercialization,” Koning says. “Longer-term, we need to shift the composition of who gets to invent and who gets to become a scientist.”
Koning, an assistant professor of business administration in the Strategy Unit at HBS, teamed up with John-Paul Ferguson of McGill University and Sampsa Samila of IESE Business School on research published in June in Science titled, Who Do We Invent For? Patents by Women Focus More on Women’s Health, but Few Women Get to Invent.
This article was provided with permission from Harvard Business School Working Knowledge.